ReviewContinuum (Minneapolis, Minn.)2014
Diabetic neuropathies.
Review in Continuum (Minneapolis, Minn.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07451431 (Efficacy, Safety and Patient-Reported Outcomes of Mirogabalin in Diabetic Peripheral Neuropathic Pain), which is not on this map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy, Safety and Patient-Reported Outcomes of Mirogabalin in Diabetic Peripheral Neuropathic Pain
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.
- ISPAD Clinical Practice Consensus Guidelines 2018: Microvascular and macrovascular complications in children and adolescents.Pediatric diabetes · 2018Guideline
- Complementary Gene Therapy after Revascularization with the Saphenous Vein in Diabetic Foot Syndrome.Genes · 2023Trial
- Vitamin B12 Supplementation in Diabetic Neuropathy: A 1-Year, Randomized, Double-Blind, Placebo-Controlled Trial.Nutrients · 2021Trial
- Trial
- Effect of Diabetic Neuropathy on Reparative Ability and Immune Response System.Molecular biotechnology · 2026Article
- Serum Uric Acid-to-Creatinine Ratio Is Independently Associated with Sudomotor Dysfunction in Type 2 Diabetes: A Cross-Sectional Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Prevalence and associated factors of peripheral neuropathy in individuals with type 2 diabetes mellitus: a cross-sectional study in Khartoum State.BMC endocrine disorders · 2025Article
- Evaluating cytidine, uridine, and gabapentin combinations for pain modulation and p-CREB expression in neuropathic model.Future science OA · 2025Article
- Machine learning models predict mortality risk in diabetic neuropathy patients using MIMIC-IV data.Scientific reports · 2025Article
- Lumbar sympathetic pulsed radiofrequency combined with continuous epidural infusion for treatment of painful diabetic neuropathy: A report of two cases and a literature review.The Journal of international medical research · 2025Review
- A forgotten frontier: spinal cord stimulation for iatrogenic and traumatic peripheral neuropathic pain.Frontiers in pain research (Lausanne, Switzerland) · 2025Article
- Management of type 2 diabetes mellitus using Yoga: Implications for immunological and autonomic dysfunction.Bioinformation · 2025Article
- Innovations in hydrogel therapies for diabetic wound healing: bridging the gap between pathophysiology and clinical application.Burns & trauma · 2025Review
- Diabetic retinopathy: A review on its pathophysiology and novel treatment modalities.World journal of methodology · 2024Review
- Glu-Ensemble: An ensemble deep learning framework for blood glucose forecasting in type 2 diabetes patients.Heliyon · 2024Article
- Hyperglycaemia Aggravates Oxidised Low-Density Lipoprotein-Induced Schwann Cell Death via Hyperactivation of Toll-like Receptor 4.Neurology international · 2024Article
- The pathophysiology of diabetic foot: a narrative review.Journal of Yeungnam medical science · 2023Article
- Diabetes mellitus differently affects electrical membrane properties of vagal afferent neurons of rats.Physiological reports · 2023Article
- Electroacupuncture Alleviates Diabetic Neuropathic Pain and Downregulates p-PKC and TRPV1 in Dorsal Root Ganglions and Spinal Cord Dorsal Horn.Evidence-based complementary and alternative medicine : eCAM · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
purpose of reviewThis article provides an overview for understanding the diagnosis, pathogenesis, and management of diabetic neuropathy. RECENT
findingsNew information about the pathogenesis of diabetic neuropathy continues to emerge, which will lead to identifying new drug targets. It is clear that the natural history of diabetic neuropathy is changing and the rate of progression is slowing. This is likely because of a combination of earlier diagnosis, improved glycemic management, and improved control of related complications such as hyperlipidemia and hypertension. Early diagnosis is critical, and small fiber neuropathy or subclinical diabetic neuropathy may be reversed or significantly improved with appropriate intervention. The American Academy of Neurology recently published guidelines for the treatment of painful diabetic neuropathy. SUMMARY: Diabetic neuropathy is common and can present with varied clinical presentations discussed in this article. Although treatment currently focuses on pain management, attention should be paid to potential risk factors for neuropathy. For example, glycemic control, hyperlipidemia, and hypertension should be managed with diet, exercise, and medications. Class I or II clinical studies indicate that pregabalin, duloxetine, amitriptyline, gabapentin, and opioids are effective in the management of diabetic neuropathic pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.